ArticleJournal of materials science. Materials in medicine2026
Enzyme-responsive release of Insulin-like Growth Factor-1 from recombinant spider-silk protein nanofibrous membrane for enhanced neural cell proliferation.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The application of biomaterial scaffolds capable of controllable growth factor release plays a pivotal role in nerve tissue repair. In this study, a recombinant fusion protein RSSP@IGF was designed and fabricated, yielding a novel recombinant spider silk protein nanofiber membrane. By integrating insulin-like growth factor-1 (IGF-1) with recombinant spider silk protein (RSSP) and incorporating specific cleavage sites responsive to thrombin and TEV protease, the construct enabled the controlled and sustained delivery of IGF-1. It was also expressed and purified using the Escherichia coli system to obtain a purity exceeding 90% RSSP@IGF. Subsequently, uniform nanofiber membranes were prepared by electrospinning. The membrane delivered excellent biocompatibility, with a hemolytic activity of 0.3%, and could significantly promote the growth of PC12 cells. Its degradation kinetics could be precisely adjusted by thrombin concentration, and 20-90% degradation achieved within 30 min at concentrations ranging from 0.1 to 4.0 U/mL. The IGF-1 release profile triggered by TEV protease showed that following its initial rapid release phase (0-24 h), its biological activity level could be maintained for up to 120 h. Notably, compared with all control groups (tissue culture plate, RSSP alone, and RSSP with soluble IGF-1), the membrane significantly enhanced PC12 cell proliferation within 10 days, demonstrating the advantage of the local delivery system. Mechanism studies revealed that RSSP@IGF may promote the proliferation of PC12 cells via the PI3K/Akt/mTOR signaling pathway. In summary, the controllable degradation spider silk protein nanofiber membrane constructed in this article provides a highly biocompatible and efficient platform for the sustained delivery of IGF-1. Its controllable degradation and sustained release characteristics hold enormous potential for applications in nerve regeneration and other fields warranting precise spatiotemporal control of growth factor presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.